¼¼°èÀÇ Ä¿½ºÅÒ ÀçÁ¶ÇÕ ´Ü¹éÁú ½ÃÀå
Custom Recombinant Proteins
»óǰÄÚµå : 1745042
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2025³â 06¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 285 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,136,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,408,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼¼°èÀÇ Ä¿½ºÅÒ ÀçÁ¶ÇÕ ´Ü¹éÁú ½ÃÀåÀº 2030³â±îÁö 100¾ï ´Þ·¯¿¡ À̸¦ Àü¸Á

2024³â¿¡ 53¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â Ä¿½ºÅÒ ÀçÁ¶ÇÕ ´Ü¹éÁú ¼¼°è ½ÃÀåÀº 2024-2030³â°£ CAGR 11.2%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 100¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ Æ÷À¯·ù ¹ßÇö ½Ã½ºÅÛÀº CAGR 12.8%¸¦ ³ªÅ¸³»°í, ºÐ¼® ±â°£ Á¾·á±îÁö 44¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¼¼±Õ ¹ßÇö ½Ã½ºÅÛ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£Áß CAGR 8.4%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 14¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 15.5%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹Ãø

¹Ì±¹ÀÇ Ä¿½ºÅÒ ÀçÁ¶ÇÕ ´Ü¹éÁú ½ÃÀåÀº 2024³â¿¡ 14¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ °æÁ¦´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 21¾ï ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ºÐ¼® ±â°£ÀÎ 2024-2030³â CAGRÀº 15.5%·Î ÃßÁ¤µË´Ï´Ù. ±âŸ ÁÖ¸ñÇØ¾ß ÇÒ Áö¿ªº° ½ÃÀåÀ¸·Î¼­´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£Áß CAGRÀº °¢°¢ 8.0%¿Í 10.1%¸¦ º¸ÀÏ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ CAGR 8.9%¸¦ º¸ÀÏ Àü¸ÁÀÔ´Ï´Ù.

¼¼°èÀÇ Ä¿½ºÅÒ ÀçÁ¶ÇÕ ´Ü¹éÁú ½ÃÀå - ÁÖ¿ä µ¿Çâ°ú ÃËÁø¿äÀÎ Á¤¸®

¸ÂÃãÇü ÀçÁ¶ÇÕ ´Ü¹éÁúÀÌ »ý¹°ÀÇÇÐ ¿¬±¸ ¹× Ä¡·áÁ¦ °³¹ß¿¡ ÇʼöÀûÀÎ ÀÌÀ¯´Â ¹«¾ùÀΰ¡?

¸ÂÃãÇü ÀçÁ¶ÇÕ ´Ü¹éÁúÀº µ¶º¸ÀûÀΠƯÀ̼º, Àϰü¼º ¹× ½ÇÇè ¼³°èÀÇ À¯¿¬¼ºÀ¸·Î ÀÎÇØ Çö´ë »ý¹° ÀÇÇÐ ¿¬±¸ ¹× ÀǾàǰ °³¹ßÀÇ ÇÙ½ÉÀÌ µÇ°í ÀÖ½À´Ï´Ù. »ýü Á¶Á÷¿¡¼­ ÃßÃâÇÑ ³×ÀÌÆ¼ºê ´Ü¹éÁú°ú ´Þ¸®, ÀçÁ¶ÇÕ ´Ü¹éÁúÀº Ç¥Àû ´Ü¹éÁúÀ» °í¼øµµ ¹× °í¼öÀ²·Î ¹ßÇöÇϵµ·Ï ¼³°èµÈ À¯ÀüÀÚ Á¶ÀÛ »ý¹°Ã¼(°¡Àå ÈçÇϰԴ ¹ÚÅ׸®¾Æ, È¿¸ð, °ïÃæ, Æ÷À¯·ù ¼¼Æ÷)¸¦ ÅëÇØ »ý»êµË´Ï´Ù. ÀÌ ¹æ¹ýÀ» ÅëÇØ °úÇÐÀÚµéÀº ´Ü¹éÁúÀÇ ¼­¿­À» ¸ÂÃãÈ­Çϰí, ű׸¦ Ãß°¡Çϰí, µ¹¿¬º¯À̸¦ µµÀÔÇÏ¿© ´Ü¹éÁúÀÇ ±â´É, ¼ö¿ëü »óÈ£ ÀÛ¿ë, È¿¼Ò ¸ÞÄ¿´ÏÁòÀ» ¿¬±¸ÇÏ´Â µ¥ ÇʼöÀûÀÎ ¼öÁØÀÇ ¸ÂÃãÈ­¸¦ °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ½Å¾à °³¹ß¿¡¼­ ¸ÂÃãÇü ´Ü¹éÁúÀº Ç×ü °³¹ßÀÇ Ç׿ø, ÇÏÀ̽º·çDz ½ºÅ©¸®´×ÀÇ Å¸°Ù, °áÁ¤ÇÐ ¹× ±ØÀú¿Â ÀüÀÚ Çö¹Ì°æÀÇ ±¸Á¶ ¸ðµ¨·Î¼­ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¾ÈÁ¤µÈ ǰÁú°ú ÀçÇö¼ºÀ¸·Î ÀÎÇØ Á¤¹Ðµµ°¡ ¿ä±¸µÇ´Â Áø´ÜŰƮ Á¦Á¶ ¹× ¹é½Å Á¦Á¦¿¡ ÀûÇÕÇÕ´Ï´Ù. ¶ÇÇÑ, ÀÌÁß Æ¯À̼º Ç×ü, À¶ÇմܹéÁú, ÀΰøÈ¿¼Ò µî ¹ÙÀÌ¿À Ä¡·áÁ¦ÀÇ º¹ÀâÈ­¿¡ µû¶ó Á¤È®ÇÑ ±¸Á¶Àû, ±â´ÉÀû ±âÁØÀ» ÃæÁ·ÇÏ´Â ¸ÂÃãÇü ´Ü¹éÁúÀÇ Á¦ÀÛÀÌ ¿ä±¸µÇ°í ÀÖ½À´Ï´Ù. ´Ü¹éÁúüÇÐ¿Í Á¤¹ÐÀÇ·áÀÇ º¸±ÞÀº Áúº´ ¹ÙÀÌ¿À¸¶Ä¿¿Í °³ÀÎÀÇ À¯ÀüÀÚ ÇÁ·ÎÆÄÀÏ¿¡ ¸ÂÃá Æ¯À̼ºÀÌ ³ôÀº ´Ü¹éÁú µµ±¸ÀÇ Çʿ伺À» ´õ¿í °­Á¶Çϰí ÀÖ½À´Ï´Ù. ±× °á°ú, ¸ÂÃãÇü ÀçÁ¶ÇÕ ´Ü¹éÁúÀº ´õ ÀÌ»ó ´Ü¼øÇÑ ½Ã¾àÀÌ ¾Æ´Ñ »ý¸í°úÇÐ, Áø´Ü ¹× ¹ÙÀÌ¿À ÀǾàǰ ÆÄÀÌÇÁ¶óÀÎ Àü¹ÝÀÇ Çõ½ÅÀ» ½ÇÇöÇÏ´Â ÇÙ½ÉÀûÀÎ Á¸Àç·Î Àνĵǰí ÀÖ½À´Ï´Ù.

±â¼ú Çõ½ÅÀº ¸ÂÃãÇü ÀçÁ¶ÇÕ ´Ü¹éÁúÀÇ ¼³°è, Á¦Á¶, Á¤Á¦¸¦ ¾î¶»°Ô Çâ»ó½Ã۰í Àִ°¡?

¸ÂÃãÇü ÀçÁ¶ÇÕ ´Ü¹éÁú ½ÃÀåÀº ´Ü¹éÁú ¹ßÇö, ¿£Áö´Ï¾î¸µ, Á¤Á¦ÀÇ ¼Óµµ, Á¤È®¼º, È®À强À» ȹ±âÀûÀ¸·Î Çâ»ó½ÃŲ ±â¼ú ¹ßÀüÀ¸·Î ÀçÆíµÇ°í ÀÖ½À´Ï´Ù. °¡Àå ¿µÇâ·Â ÀÖ´Â ¹ßÀü Áß Çϳª´Â CRISPR ¹× ±âŸ À¯Àüü ÆíÁý µµ±¸¸¦ »ç¿ëÇÏ¿© ¼÷ÁÖ ¼¼Æ÷ÁÖ¸¦ ÃÖÀûÈ­ÇÏ¿© º¸´Ù È¿À²ÀûÀÎ À¯ÀüÀÚ ÅëÇÕ ¹× ¹ßÇöÀ» °¡´ÉÇÏ°Ô ÇÑ °ÍÀÔ´Ï´Ù. ¹ßÇö ½Ã½ºÅÛ ÀÚüµµ ´Ù¾çÈ­µÇ¾î Æ÷À¯·ù ¼¼Æ÷°¡ º¹ÀâÇÑ ¹ø¿ª ÈÄ º¯Çü¿¡ À¯¸®ÇÑ ¹Ý¸é, ¹ÚÅ׸®¾Æ¿Í È¿¸ð ½Ã½ºÅÛÀº ºü¸£°í ºñ¿ë È¿À²ÀûÀÎ ´Ü¹éÁú »ý»ê¿¡ ÇʼöÀûÀ̶ó´Â »ç½ÇÀº º¯ÇÔÀÌ ¾ø½À´Ï´Ù. ÷´Ü º¤ÅÍ¿Í ÇÁ·Î¸ðÅÍ´Â ÇöÀç ¾ö°ÝÇÑ ¹ßÇö Á¦¾î¿Í ³ôÀº ¼öÀ²À» °¡´ÉÇÏ°Ô ÇÏ¿© ¿¬±¸¿ë ¹× Ä¡·á¿ë ´Ü¹éÁú ½ÃÀå Ãâ½Ã ½Ã°£À» ´ÜÃàÇϰí ÀÖ½À´Ï´Ù. ÄÚµ· ÃÖÀûÈ­, ½ÅÈ£ ÆéŸÀÌµå µðÀÚÀÎ, Æúµù »þÆä·ÐÀÇ Çõ½ÅÀº ´Ü¹éÁúÀÇ ¿ëÇØµµ¿Í ±â´É¼ºÀ» Çâ»ó½ÃÄ×½À´Ï´Ù. Á¤Á¦ Ãø¸é¿¡¼­´Â Ä£ È­¼º Å©·Î¸¶Åä±×·¡ÇÇ, ÀÚµ¿ ¾×ü ó¸® ½Ã½ºÅÛ, °íÇØ»óµµ Áú·® ºÐ¼®±â¸¦ ÅëÇØ ¹ßÇöÀÌ ¾î·Á¿î ´Ü¹éÁúµµ ³ôÀº ¼øµµ ¼öÁذú ±¸Á¶Àû ¹«°á¼ºÀ» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, AI¸¦ Ȱ¿ëÇÑ ´Ü¹éÁú ¼³°è Ç÷§ÆûÀÌ ¾ÈÁ¤¼º, ¸é¿ª¿ø¼º, Ȱ¼º ¿¹Ãø¿¡ »ç¿ëµÇ¾î ÇÕ¼ºÀÌ ½ÃÀ۵DZâ ÀüºÎÅÍ ´Ü¹éÁú º¯ÀÌü¸¦ º¸´Ù Áö´ÉÀûÀ¸·Î ¼³°èÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ±â¾÷µéÀº ¶ÇÇÑ ¿¬±¸ÀÚµéÀÌ À¯ÀüÀÚ ¼­¿­À» Á¦ÃâÇÏ°í ´Ü ¸î ÁÖ ¸¸¿¡ Á¤Á¦µÈ ¸ÂÃãÇü ´Ü¹éÁúÀ» ¹ÞÀ» ¼ö ÀÖ´Â ¿£µåÅõ¿£µå ÀÚµ¿È­ ¹× Ŭ¶ó¿ìµå ±â¹Ý Ç÷§Æû¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀû °³¼±Àº »ý¹°ÇÐÀû ¹ß°ß°ú Ä¡·á¹ý Çõ½ÅÀÇ ¼Óµµ¸¦ °¡¼ÓÈ­ÇÏ°í ¸ÂÃãÇü ÀçÁ¶ÇÕ ´Ü¹éÁú ¼­ºñ½ºÀÇ ½Å·Ú¼º, Á¢±Ù¼º, Çʼö¼ºÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù.

¸ÂÃãÇü ÀçÁ¶ÇÕ ´Ü¹éÁú ¼ö¿ä Áõ°¡¸¦ ÁÖµµÇÏ´Â »ê¾÷ ¹× ¿¬±¸ µ¿ÇâÀº?

¸ÂÃãÇü ÀçÁ¶ÇÕ ´Ü¹éÁú¿¡ ´ëÇÑ ¼ö¿ä´Â Á¦¾à °³¹ß, Áø´Ü, ³ó¾÷ ¹× Çмú °úÇп¡ °ÉÄ£ ´Ù¾çÇÑ »ê¾÷ ¹× ¿¬±¸ µ¿Çâ¿¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. Á¦¾à ºÐ¾ß¿¡¼­´Â »ý¹°ÇÐÀû Á¦Á¦ ¹× ¹ÙÀÌ¿À½Ã¹Ð·¯ÀÇ µîÀåÀ¸·Î ¼¼Æ÷ ±â¹Ý ºÐ¼®, µ¶¼º Å×½ºÆ® ¹× Á¦Á¦ °³¹ß¿¡ »ç¿ëµÇ´Â ¸ÂÃãÇü ´Ü¹éÁú¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¸é¿ª¿ä¹ý°ú Ç¥ÀûÄ¡·áÁ¦°¡ ºÎ»óÇϸ鼭 Á¦¾àȸ»çµéÀº ±â¼ºÇ°º¸´Ù ´õ Á¤È®ÇÏ°Ô Àΰ£ÀÇ »ý¸®Àû ±â´ÉÀ» ¸ð¹æÇÑ ¸ÂÃãÇü »çÀÌÅäÄ«ÀÎ, ¼ºÀåÀÎÀÚ, üũÆ÷ÀÎÆ® ´Ü¹éÁúÀ» ¿ä±¸Çϰí ÀÖ½À´Ï´Ù. Áø´ÜÇп¡¼­´Â Á¤¹ÐÀÇ·áÀÇ ÃßÁøÀ¸·Î ¸é¿ªºÐ¼®À̳ª ELISA¿¡¼­ ƯÀÌÀûÀÎ ¹ÙÀÌ¿À¸¶Ä¿³ª °ËÃâ Ÿ°ÙÀÌ µÇ´Â ÀçÁ¶ÇÕ ´Ü¹éÁúÀÇ Ã¢ÃâÀÌ ÁøÇàµÇ°í ÀÖ½À´Ï´Ù. ¿¬±¸±â°üµéµµ ±¸Á¶Àû ¹× ±â´ÉÀû ´Ü¹éÁúüÇп¡ ´ëÇÑ ÅõÀÚ¸¦ ´Ã¸®°í ÀÖÀ¸¸ç, ºÎÀ§º° º¯Çü, Çü±¤ ű×, µ¹¿¬º¯ÀÌ ÆÐ³ÎÀ» °¡Áø Àΰø ´Ü¹éÁú¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ³ó¾÷ »ý¸í°øÇеµ ½ÅÈï ½ÃÀå Áß ÇϳªÀ̸ç, ¸ÂÃãÇü ´Ü¹éÁúÀº ½Ä¹° ¸é¿ª ¿¬±¸, ³»º´¼º ÀÛ¹° °³¹ß, È¿¼Ò ±â¹Ý ºñ·á °³¹ß¿¡ »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ±³À° ¿¬±¸¼Ò¿Í CRO´Â ³³±â¸¦ ´ÜÃàÇÏ°í ½ÇÇèÀÇ Á¤È®¼ºÀ» À¯ÁöÇϱâ À§ÇØ ÀçÁ¶ÇÕ ´Ü¹éÁú ¼­ºñ½º¸¦ äÅÃÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Äڷγª19 ÆÒµ¥¹ÍÀº ½Å¼ÓÇÑ ¹é½Å °³¹ß, Ç×ü °Ë»ç, Ä¡·á ½ºÅ©¸®´×¿¡¼­ ÀçÁ¶ÇÕ ´Ü¹éÁúÀÇ Á߿伺À» ºÎ°¢½Ã۸ç, ÀçÁ¶ÇÕ ´Ü¹éÁúÀÇ ¼¼°è ÀÎÁöµµ¿Í ÀÎÁöµµ¸¦ °¡¼ÓÈ­Çß½À´Ï´Ù. ÀÌ·¯ÇÑ ±¤¹üÀ§ÇÑ ÀÀ¿ë ºÐ¾ß´Â ±âÁ¸ ¹× ½ÅÈï °úÇÐ ºÐ¾ß ¸ðµÎ¿¡¼­ ¹ß°ß, Çõ½Å ¹× Á¦Ç° °³¹ßÀ» ÃËÁøÇÏ´Â µ¥ ÀÖ¾î ¸ÂÃãÇü ´Ü¹éÁúÀÇ Á߿伺À» °­Á¶Çϰí ÀÖ½À´Ï´Ù.

¼¼°è ¸ÂÃãÇü ÀçÁ¶ÇÕ ´Ü¹éÁú ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?

¼¼°è ¸ÂÃãÇü ÀçÁ¶ÇÕ ´Ü¹éÁú ½ÃÀåÀº R&:D ÅõÀÚ Áõ°¡, ¸¸¼ºÁúȯ ¹× À¯Àü¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, ¸ÂÃãÇü ÀÇ·á·ÎÀÇ Àüȯ °¡¼ÓÈ­ µîÀÇ ¿äÀÎÀÌ º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ¿© °­·ÂÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. ÁÖ¿ä ÃËÁø¿äÀÎÀº Á¶±â ¹ß°ßºÎÅÍ ÀÓ»ó °ËÁõ±îÁö ¸ðµç ´Ü°è¿¡¼­ ¸ÂÃãÇü ´Ü¹éÁúÀ» ÇÊ¿ä·Î ÇÏ´Â ¹ÙÀÌ¿À ÀǾàǰ ÆÄÀÌÇÁ¶óÀÎÀÇ È®´ëÀÔ´Ï´Ù. ´ÜŬ·Ð Ç×ü, ¹é½Å, À¯ÀüÀÚ Ä¡·áÁ¦¸¦ Æ÷ÇÔÇÑ »ý¹°ÇÐÀû Á¦Á¦ÀÇ Àü ¼¼°è ±ÞÁõÀº À¯È¿¼º ½ÃÇè°ú ±ÔÁ¦ Áؼö¸¦ À§ÇØ ¸ÂÃãÇü ´Ü¹éÁúÀÇ ¾ÈÁ¤ÀûÀÎ °ø±ÞÀ» ÇÊ¿ä·Î ÇÕ´Ï´Ù. ¶ÇÇÑ, »ý¸í°úÇÐ ¿¬±¸¿¡ ´ëÇÑ Á¤ºÎ ¹× ¹Î°£ ºÎ¹®ÀÇ ÀÚ±Ý Áö¿øÀº ƯÈ÷ À¯Àüü ¿¬±¸, Á¾¾ç ¿¬±¸, °¨¿°¼º Áúȯ ¿¬±¸¿¡¼­ ¿ª»çÀûÀÎ ¼öÁØ¿¡ À̸£·¶À¸¸ç, ÀÌ´Â ´Ü¹éÁú ¸ÂÃãÇü ¼­ºñ½º¸¦ À§ÇÑ ºñ¿ÁÇÑ Åä¾çÀ» Á¶¼ºÇϰí ÀÖ½À´Ï´Ù. °íÀ¯ÇÑ ´Ü¹éÁú ±¸Á¶¿¡ ´ëÇÑ ½Å¼ÓÇÏ°í ½Å·ÚÇÒ ¼ö ÀÖ´Â Á¢±ÙÀ» ¿øÇÏ´Â »êÇÐÇù·Â°ú CRO(ÀÓ»ó½ÃÇè¼öʱâ°ü) Áõ°¡·Î °í°´ ±â¹ÝÀÌ ´õ¿í È®´ëµÇ°í ÀÖ½À´Ï´Ù. ½ÅÈï±¹µéµµ ¹ÙÀÌ¿ÀÅ×Å©³î·¯ÁöÀÇ ¿ª·®À» °­È­Çϸ鼭 ÇöÁöÈ­µÈ ¸ÂÃãÇü ´Ü¹éÁú »ý»ê ¼­ºñ½º¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, FDA ¹× EMA¿Í °°Àº ±ÔÁ¦ ±â°üÀº ÇöÀç »ý¹°ÇÐÀû Á¦Á¦¿¡ ´ëÇÑ ¾ö°ÝÇÑ °ËÁõÀ» °­Á¶Çϰí ÀÖ¾î °íǰÁúÀÇ ÃßÀû °¡´ÉÇÑ ´Ü¹éÁú ½Ã¾à¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Çʿ伺ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ±â¼ºÇ°À¸·Î Á¶´ÞÇÒ ¼ö ¾ø´Â º¹ÀâÇÑ ´ÙÁß µµ¸ÞÀÎ ¹× À¶ÇÕ ´Ü¹éÁúÀ» Ãß±¸ÇÏ´Â ¿¬±¸ÀÚµéÀÌ ´Ã¾î³²¿¡ µû¶ó ¸ÂÃãÇü ÀçÁ¶ÇÕ ¼Ö·ç¼ÇÀÇ ¸Å·ÂÀº Á¡Á¡ ´õ Ä¿Áö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎÀº ±â¼úÀû È®À强 ¹× ³³±â °³¼±°ú ÇÔ²² ¼¼°è ¸ÂÃãÇü ÀçÁ¶ÇÕ ´Ü¹éÁú ½ÃÀåÀÇ Àå±âÀûÀÎ »ýÁ¸°ú ¼ºÀåÀ» º¸ÀåÇϰí ÀÖ½À´Ï´Ù.

ºÎ¹®

¹ßÇö°è(Æ÷À¯·ù, ¼¼±Õ, °ïÃæ, È¿¸ð, ±âŸ ¹ßÇö°è);ÃÖÁ¾»ç¿ëÀÚ(¿¬±¸±â°ü, Á¦¾à ±â¾÷ ¹× ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷, °è¾à ¿¬±¸±â°ü, ±âŸ ÃÖÁ¾»ç¿ëÀÚ)

Á¶»ç ´ë»ó ±â¾÷ ¿¹(ÃÑ 39°³»ç)

°ü¼¼ ¿µÇâ °è¼ö

Global Industry Analysts´Â º»»çÀÇ ±¹°¡, Á¦Á¶°ÅÁ¡, ¼öÃâÀÔ(¿ÏÁ¦Ç° ¹× OEM)À» ±â¹ÝÀ¸·Î ±â¾÷ÀÇ °æÀï·Â º¯È­¸¦ ¿¹ÃøÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¹ÀâÇÏ°í ´Ù¸éÀûÀÎ ½ÃÀå ¿ªÇÐÀº ÀÎÀ§ÀûÀÎ ¼öÀÍ¿ø°¡ Áõ°¡, ¼öÀͼº °¨¼Ò, °ø±Þ¸Á ÀçÆí µî ¹Ì½ÃÀû ¹× °Å½ÃÀû ½ÃÀå ¿ªÇÐ Áß¿¡¼­µµ ƯÈ÷ °æÀï»çµé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

Global Industry Analysts´Â ¼¼°è ÁÖ¿ä ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ®(1,4,949¸í), ½ÌÅ©ÅÊÅ©(62°³ ±â°ü), ¹«¿ª ¹× »ê¾÷ ´Üü(171°³ ±â°ü)ÀÇ Àü¹®°¡µéÀÇ ÀǰßÀ» ¸é¹ÐÈ÷ °ËÅäÇÏ¿© »ýŰ迡 ¹ÌÄ¡´Â ¿µÇâÀ» Æò°¡ÇÏ°í »õ·Î¿î ½ÃÀå Çö½Ç¿¡ ´ëÀÀÇϰí ÀÖ½À´Ï´Ù. ¸ðµç ÁÖ¿ä ±¹°¡ÀÇ Àü¹®°¡¿Í °æÁ¦ÇÐÀÚµéÀÌ °ü¼¼¿Í ±×°ÍÀÌ ÀÚ±¹¿¡ ¹ÌÄ¡´Â ¿µÇâ¿¡ ´ëÇÑ ÀǰßÀ» ÃßÀû Á¶»çÇß½À´Ï´Ù.

Global Industry Analysts´Â ÀÌ·¯ÇÑ È¥¶õÀÌ ÇâÈÄ 2-3°³¿ù ³»¿¡ ¸¶¹«¸®µÇ°í »õ·Î¿î ¼¼°è Áú¼­°¡ º¸´Ù ¸íÈ®ÇÏ°Ô È®¸³µÉ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, Global Industry Analysts´Â ÀÌ·¯ÇÑ »óȲÀ» ½Ç½Ã°£À¸·Î ÃßÀûÇϰí ÀÖ½À´Ï´Ù.

2025³â 4¿ù: Çù»ó ´Ü°è

À̹ø 4¿ù º¸°í¼­¿¡¼­´Â °ü¼¼°¡ ¼¼°è ½ÃÀå Àüü¿¡ ¹ÌÄ¡´Â ¿µÇâ°ú Áö¿ªº° ½ÃÀå Á¶Á¤¿¡ ´ëÇØ ¼Ò°³ÇÕ´Ï´Ù. ´ç»çÀÇ ¿¹ÃøÀº °ú°Å µ¥ÀÌÅÍ¿Í ÁøÈ­ÇÏ´Â ½ÃÀå ¿µÇâ¿äÀÎÀ» ±â¹ÝÀ¸·Î ÇÕ´Ï´Ù.

2025³â 7¿ù: ÃÖÁ¾ °ü¼¼ Àç¼³Á¤

°í°´´Ôµé²²´Â °¢ ±¹°¡º° ÃÖÁ¾ ¸®¼ÂÀÌ ¹ßÇ¥µÈ ÈÄ 7¿ù¿¡ ¹«·á ¾÷µ¥ÀÌÆ® ¹öÀüÀ» Á¦°øÇØ µå¸³´Ï´Ù. ÃÖÁ¾ ¾÷µ¥ÀÌÆ® ¹öÀü¿¡´Â ¸íÈ®ÇÏ°Ô Á¤ÀÇµÈ °ü¼¼ ¿µÇ⠺м®ÀÌ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù.

»óÈ£ ¹× ¾çÀÚ °£ ¹«¿ª ¹× °ü¼¼ ¿µÇ⠺м® :

¹Ì±¹ <>& Áß±¹ <>& ¸ß½ÃÄÚ <>& ij³ª´Ù <>&EU <>& ÀϺ» <>& Àεµ <>& ±âŸ 176°³±¹

¾÷°è ÃÖ°íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®: Global Industry AnalystsÀÇ Áö½Ä ±â¹ÝÀº ±¹°¡, ½ÌÅ©ÅÊÅ©, ¹«¿ª ¹× »ê¾÷ ´Üü, ´ë±â¾÷, ±×¸®°í ¼¼°è °è·®°æÁ¦ »óȲ¿¡¼­ ÀÌ Àü·Ê ¾ø´Â ÆÐ·¯´ÙÀÓ ÀüȯÀÇ ¿µÇâÀ» °øÀ¯ÇÏ´Â ºÐ¾ßº° Àü¹®°¡ µî °¡Àå ¿µÇâ·Â ÀÖ´Â ¼ö¼® ÀÌÄÚ³ë¹Ì½ºÆ® ±×·ìÀ» Æ÷ÇÔÇÑ 14,949¸íÀÇ ÀÌÄÚ³ë¹Ì½ºÆ®¸¦ ÃßÀûÇϰí ÀÖ½À´Ï´Ù. 16,491°³ ÀÌ»óÀÇ º¸°í¼­ ´ëºÎºÐ¿¡ ¸¶ÀϽºÅæ¿¡ ±â¹ÝÇÑ 2´Ü°è Ãâ½Ã ÀÏÁ¤ÀÌ Àû¿ëµÇ¾î ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

LSH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Custom Recombinant Proteins Market to Reach US$10.0 Billion by 2030

The global market for Custom Recombinant Proteins estimated at US$5.3 Billion in the year 2024, is expected to reach US$10.0 Billion by 2030, growing at a CAGR of 11.2% over the analysis period 2024-2030. Mammalian Expression System, one of the segments analyzed in the report, is expected to record a 12.8% CAGR and reach US$4.4 Billion by the end of the analysis period. Growth in the Bacteria Expression System segment is estimated at 8.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 15.5% CAGR

The Custom Recombinant Proteins market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.1 Billion by the year 2030 trailing a CAGR of 15.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.0% and 10.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.9% CAGR.

Global Custom Recombinant Proteins Market - Key Trends & Drivers Summarized

Why Are Custom Recombinant Proteins Becoming Essential in Biomedical Research and Therapeutic Development?

Custom recombinant proteins are increasingly becoming the backbone of modern biomedical research and drug development due to their unparalleled specificity, consistency, and flexibility in experimental design. Unlike native proteins extracted from biological tissues, recombinant proteins are produced via genetically engineered organisms-most commonly bacteria, yeast, insect, or mammalian cells-designed to express target proteins in high purity and yield. This method allows scientists to tailor protein sequences, add tags, or introduce mutations, offering a level of customization that is vital for studying protein function, receptor interactions, and enzyme mechanisms. In drug discovery, custom proteins serve as antigens in antibody development, targets for high-throughput screening, and structural models in crystallography and cryo-electron microscopy. Their consistent quality and reproducibility make them ideal for diagnostic kit manufacturing and vaccine formulation, where precision is non-negotiable. Moreover, the growing complexity of biotherapeutics-such as bispecific antibodies, fusion proteins, and engineered enzymes-has necessitated the creation of custom proteins that meet exact structural and functional criteria. The increasing adoption of proteomics and precision medicine further underscores the need for highly specific protein tools tailored to disease biomarkers or individual genetic profiles. As a result, custom recombinant proteins are no longer viewed as mere reagents but as central enablers of innovation across life sciences, diagnostics, and biopharmaceutical pipelines.

How Are Technological Innovations Enhancing the Design, Production, and Purification of Custom Recombinant Proteins?

The custom recombinant proteins market is being reshaped by technological advancements that have dramatically improved the speed, accuracy, and scalability of protein expression, engineering, and purification. One of the most impactful developments is the use of CRISPR and other genome editing tools to optimize host cell lines, enabling more efficient gene integration and expression. Expression systems themselves have diversified, with mammalian cells favored for complex post-translational modifications, while bacterial and yeast systems remain essential for rapid and cost-effective protein production. Advanced vectors and promoters now allow for tightly regulated expression and higher yields, reducing time to market for research and therapeutic proteins. Innovations in codon optimization, signal peptide design, and folding chaperones have enhanced protein solubility and functionality. On the purification front, affinity chromatography, automated liquid handling systems, and high-resolution mass spectrometry are ensuring high purity levels and structural integrity, even in difficult-to-express proteins. Moreover, AI-driven protein design platforms are now being used to predict stability, immunogenicity, and activity, allowing for more intelligent engineering of protein variants before synthesis even begins. Companies are also investing in end-to-end automation and cloud-based platforms that allow researchers to submit gene sequences and receive purified custom proteins in just weeks. These technological improvements are accelerating the pace of biological discovery and therapeutic innovation, making custom recombinant protein services more reliable, accessible, and indispensable.

What Industry and Research Trends Are Driving the Increasing Demand for Custom Recombinant Proteins?

The demand for custom recombinant proteins is being propelled by a host of industry and research trends that span pharmaceutical development, diagnostics, agriculture, and academic science. In the pharmaceutical sector, the rise of biologics and biosimilars has dramatically increased the need for customized proteins for use in cell-based assays, toxicity testing, and formulation development. As immunotherapy and targeted therapies gain ground, pharmaceutical companies are requesting custom cytokines, growth factors, and checkpoint proteins that mimic human physiology more accurately than off-the-shelf alternatives. In diagnostics, the push for precision medicine has led to the creation of recombinant proteins that serve as specific biomarkers or detection targets in immunoassays and ELISAs. Research institutions are also investing more in structural and functional proteomics, driving demand for engineered proteins with site-specific modifications, fluorescent tags, or mutation panels. Agricultural biotechnology is another emerging market, where custom proteins are used to study plant immunity, develop disease-resistant crops, and engineer enzyme-based fertilizers. Educational labs and CROs are adopting recombinant protein services to reduce turnaround times and maintain experimental rigor. Furthermore, the COVID-19 pandemic spotlighted the importance of recombinant proteins in rapid vaccine development, antibody testing, and therapeutic screening-accelerating their global visibility and perceived value. These broad-based applications underscore the centrality of custom proteins in fueling discovery, innovation, and product development across both established and emerging scientific fields.

What Are the Key Drivers Fueling Growth in the Global Custom Recombinant Proteins Market?

The global custom recombinant proteins market is experiencing robust growth driven by converging forces such as rising R&D investments, increasing prevalence of chronic and genetic diseases, and the accelerating shift toward personalized medicine. A primary growth driver is the expansion of biopharmaceutical pipelines, where tailored proteins are required for every stage from early discovery to clinical validation. The global surge in biologics-including monoclonal antibodies, vaccines, and gene therapies-necessitates the consistent supply of customized proteins for efficacy testing and regulatory compliance. Additionally, government and private sector funding for life sciences research has reached historic levels, particularly in genomics, oncology, and infectious disease studies, creating a fertile ground for protein customization services. The growing number of academic-industry collaborations and contract research organizations (CROs) seeking quick, reliable access to unique protein constructs further expands the customer base. Emerging economies are also ramping up their biotechnology capabilities, increasing demand for localized, customizable protein production services. Regulatory agencies like the FDA and EMA now emphasize rigorous validation of biologics, increasing the need for high-quality, traceable protein reagents. As more researchers pursue complex, multi-domain, and fusion proteins that cannot be sourced off-the-shelf, the appeal of bespoke recombinant solutions continues to rise. Coupled with technological scalability and improvements in delivery timelines, these drivers are ensuring the long-term viability and growth of the global custom recombinant proteins market.

SCOPE OF STUDY:

The report analyzes the Custom Recombinant Proteins market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Expression System (Mammalian, Bacteria, Insect, Yeast, Other Expression Systems); End-User (Research Institutes, Pharma & Biotech Companies, Contract Research Organizations, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â